ATLANTA – Femasys Inc. (Nasdaq: FEMY), a leading biomedical innovator in women’s health, has received regulatory approval from the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) for three of its groundbreaking products. The approvals include FemaSeed, an intratubal insemination device for female infertility treatment, along with FemVue for tubal evaluation and FemCerv for cervical cancer detection.
“This marks another significant milestone as we expand into the UK following successful approval across Europe,” said Kathy Lee-Sepsick, CEO of Femasys. “We are dedicated to providing innovative, safe, and effective solutions to address critical unmet needs in women’s healthcare worldwide.”
With these approvals, Femasys continues to advance its mission of delivering accessible, in-office therapeutic and diagnostic options for infertility and cancer detection, reinforcing its impact on global women’s health.
Related topics:
Factors Reducing Sperm Count: Are You Making These Mistakes?
Oura’s Fertile Window Feature Surpasses Calendar Method in Ovulation Predictions
Trump Claims ‘Father of IVF’ at Georgia Event to Appeal to Female Voters
